Logotype for ProQR Therapeutics N.V.

ProQR Therapeutics (PRQR) investor relations material

ProQR Therapeutics Chardan’s 9th Annual Genetic Medicines Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for ProQR Therapeutics N.V.
Chardan’s 9th Annual Genetic Medicines Conference summary21 Oct, 2025

Advances in ADAR RNA editing and clinical translation

  • Clinical data now show successful RNA editing in patients, with alpha-1 antitrypsin deficiency (AATD) as a lead indication, demonstrating conversion from Z to M protein and durable, physiologically relevant protein levels after dosing.

  • Editing approaches using GalNAc-conjugated oligos enable subcutaneous delivery, rapid onset, and sustained effects, with ongoing studies to optimize dose and durability, including higher dose cohorts and less frequent dosing intervals.

  • Preclinical and early clinical data support the ability to mount acute phase responses and achieve MZ-like phenotypes, with plans to further engage regulatory agencies and expand to additional targets.

  • AIRNA and others are leveraging advances in chemistry and oligo design to engage multiple ADAR isoforms, with preclinical data showing high protein levels and long durability in animal models, and clinical entry planned by year-end.

  • ProQR’s lead, AX-0810, targets NTCP for cholestatic diseases, with phase 1 clearance and a focus on modulating protein function, not just correction, and CNS programs showing broad distribution and high editing efficiency.

Platform evolution, target selection, and field outlook

  • Companies are using learnings from AATD to de-risk and expand pipelines, with new targets like PNPLA3 for liver disease and precision edits for protein-protein interactions, focusing on liver indications with clear biomarkers.

  • The field is rapidly approaching the platform maturity seen in siRNA, with improved understanding of enzyme behavior, translation from animal to human, and the importance of target selection and biomarker association.

  • Endogenous ADAR’s precision and catalytic activity in humans is now well validated, enabling transient, reversible edits and reducing concerns about off-target effects or immune responses.

  • Investor focus is shifting from enzyme function to indication selection and proof of concept, with ongoing debate about editing efficiency versus DNA editing and the breadth of potential applications.

  • The chemical toolbox and delivery strategies are well established, supporting faster clinical translation and the expectation that RNA editing will reach broad applicability more quickly than previous modalities.

Industry collaboration and future directions

  • Partnerships with pharma and research organizations are accelerating CNS and liver programs, with confidential targets and ongoing collaborations to expand the reach of RNA editing.

  • Panelists agree that the next wave of clinical data and target expansion will further validate the technology, with the first drugs likely to be followed by improved generations as the field matures.

  • The focus is on translating clinical learnings back to preclinical models to refine platform capabilities and accelerate the path from target identification to human trials.

  • There is consensus that RNA editing is poised for rapid growth, with the potential to address a wide range of genetic and protein-modulation diseases beyond current knockdown approaches.

  • The session concluded with optimism about the pace of progress and the shift from theoretical enzyme discussions to practical therapeutic development.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next ProQR Therapeutics earnings date

Logotype for ProQR Therapeutics N.V.
Study Update3 Nov, 2025
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next ProQR Therapeutics earnings date

Logotype for ProQR Therapeutics N.V.
Study Update3 Nov, 2025

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

ProQR Therapeutics N.V. is a biotechnology company focused on developing innovative RNA therapies for genetic diseases. Established in 2012 in Leiden, Netherlands, ProQR pioneers RNA editing technologies, specifically its proprietary platform called Axiomer. This technology enables precise RNA editing by using a cell's own ADAR enzymes to alter specific nucleotides in RNA molecules, potentially reversing mutations or modulating protein expression to address unmet medical needs in various diseases. The company's approach to drug development is particularly significant for conditions that currently lack effective treatments. Over the years, ProQR has expanded its pipeline beyond its initial focus on cystic fibrosis to include a range of rare and common diseases, with ongoing research and development efforts in fields such as inherited retinal diseases and liver diseases. The company is headquartered in Leiden, Netherlands, and its shares are listed on the NASDAQ.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage